Investor mix
3 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 1 | 33% |
| Other / undisclosed | 2 | 67% |
Swedish, late clinical stage biopharma developing topical antivirals for epidemic keratoconjunctivitis
3 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 1 | 33% |
| Other / undisclosed | 2 | 67% |